ClinicalTrials.gg

Program

CKD-508

A development code. Also written as “CKD-508 Tablet” and “CKD-508 Capsule”.

Its studies are led by Chong Kun Dang Pharmaceutical.

Furthest: phase 1, since Jul 22, 20203 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chong Kun Dang Pharmaceutical30 open or runningphase 1since Jul 22, 2020Jul 22, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 22, 2020First study: phase 1 study in Healthy SubjectsFirst studyNCT04488900 · 88 enrolled · United Kingdom
  2. Dec 2, 2024Phase 1 study in Healthy SubjectsNCT06727396 · 44 enrolled · United States
  3. May 9, 2025Phase 1 study in HealthyNCT06979973 · 24 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06979973Healthy · United States1CompletedAug 17, 202524
NCT06727396Healthy Subjects · United States1CompletedJun 5, 202544
NCT04488900Healthy Subjects · United Kingdom1CompletedJul 2, 202388

How it is read

Names in the registry

  • “CKD-508 Tablet”, 3 entries
  • “CKD-508 Capsule”, 1 entry

Codes read as this program: CKD508.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.